Cargando…

Computational strategies towards developing novel SARS-CoV-2 M(pro) inhibitors against COVID-19

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains to be a serious threat due to the lack of a specific therapeutic agent. Computational methods are particularly suitable for rapidly fight against SARS-CoV-2. This present research aims to systematica...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Ding, Tong, Jian-Bo, Zhang, Xing, Xiao, Xue-Chun, Bian, Shuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398673/
https://www.ncbi.nlm.nih.gov/pubmed/34483363
http://dx.doi.org/10.1016/j.molstruc.2021.131378
_version_ 1783744895675006976
author Luo, Ding
Tong, Jian-Bo
Zhang, Xing
Xiao, Xue-Chun
Bian, Shuai
author_facet Luo, Ding
Tong, Jian-Bo
Zhang, Xing
Xiao, Xue-Chun
Bian, Shuai
author_sort Luo, Ding
collection PubMed
description The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains to be a serious threat due to the lack of a specific therapeutic agent. Computational methods are particularly suitable for rapidly fight against SARS-CoV-2. This present research aims to systematically explore the interaction mechanism of a series of novel bicycloproline-containing SARS-CoV-2 M(pro) inhibitors through integrated computational approaches. We designed six structurally modified novel SARS-CoV-2 M(pro) inhibitors based on the QSAR study. The four designed compounds with higher docking scores were further explored through molecular docking, molecular dynamics (MD) simulations, free energy calculations, and residual energy contributions estimated by the MM-PBSA approach, with comparison to compound 23(PDB entry 7D3I). This research not only provides robust QSAR models as valuable screening tools for the development of anti-COVID-19 drugs, but also proposes the newly designed SARS-CoV-2 M(pro) inhibitors with nanomolar activities that can be potentially used for further characterization to treat SARS-CoV-2 virus.
format Online
Article
Text
id pubmed-8398673
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-83986732021-08-30 Computational strategies towards developing novel SARS-CoV-2 M(pro) inhibitors against COVID-19 Luo, Ding Tong, Jian-Bo Zhang, Xing Xiao, Xue-Chun Bian, Shuai J Mol Struct Article The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains to be a serious threat due to the lack of a specific therapeutic agent. Computational methods are particularly suitable for rapidly fight against SARS-CoV-2. This present research aims to systematically explore the interaction mechanism of a series of novel bicycloproline-containing SARS-CoV-2 M(pro) inhibitors through integrated computational approaches. We designed six structurally modified novel SARS-CoV-2 M(pro) inhibitors based on the QSAR study. The four designed compounds with higher docking scores were further explored through molecular docking, molecular dynamics (MD) simulations, free energy calculations, and residual energy contributions estimated by the MM-PBSA approach, with comparison to compound 23(PDB entry 7D3I). This research not only provides robust QSAR models as valuable screening tools for the development of anti-COVID-19 drugs, but also proposes the newly designed SARS-CoV-2 M(pro) inhibitors with nanomolar activities that can be potentially used for further characterization to treat SARS-CoV-2 virus. Elsevier B.V. 2022-01-05 2021-08-28 /pmc/articles/PMC8398673/ /pubmed/34483363 http://dx.doi.org/10.1016/j.molstruc.2021.131378 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Luo, Ding
Tong, Jian-Bo
Zhang, Xing
Xiao, Xue-Chun
Bian, Shuai
Computational strategies towards developing novel SARS-CoV-2 M(pro) inhibitors against COVID-19
title Computational strategies towards developing novel SARS-CoV-2 M(pro) inhibitors against COVID-19
title_full Computational strategies towards developing novel SARS-CoV-2 M(pro) inhibitors against COVID-19
title_fullStr Computational strategies towards developing novel SARS-CoV-2 M(pro) inhibitors against COVID-19
title_full_unstemmed Computational strategies towards developing novel SARS-CoV-2 M(pro) inhibitors against COVID-19
title_short Computational strategies towards developing novel SARS-CoV-2 M(pro) inhibitors against COVID-19
title_sort computational strategies towards developing novel sars-cov-2 m(pro) inhibitors against covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398673/
https://www.ncbi.nlm.nih.gov/pubmed/34483363
http://dx.doi.org/10.1016/j.molstruc.2021.131378
work_keys_str_mv AT luoding computationalstrategiestowardsdevelopingnovelsarscov2mproinhibitorsagainstcovid19
AT tongjianbo computationalstrategiestowardsdevelopingnovelsarscov2mproinhibitorsagainstcovid19
AT zhangxing computationalstrategiestowardsdevelopingnovelsarscov2mproinhibitorsagainstcovid19
AT xiaoxuechun computationalstrategiestowardsdevelopingnovelsarscov2mproinhibitorsagainstcovid19
AT bianshuai computationalstrategiestowardsdevelopingnovelsarscov2mproinhibitorsagainstcovid19